CDIO
Cardio Diagnostics Holdings, Inc.
There isn't enough reported data to score CDIO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CDIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
CDIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CDIO PE Valuation
CDIO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CDIO Forward outlook
There aren't enough analyst estimates for CDIO to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CDIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$9.60 | +$53.50 |
| Q2 2024 | -$12.60 | +$45.06 |
| Q1 2024 | -$22.50 | +$25.28 |
| Q4 2023 | -$19.80 | +$25.50 |
| Q3 2023 | -$63.10 | -$61.08 |
| Q2 2023 | -$57.66 | -$55.00 |
| Q1 2023 | -$47.78 | -$46.93 |
| Q4 2022 | -$45.30 | -$45.26 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 126% for CDIO versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
CDIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.6K | +26% |
| Q2 2026 | $5.4K | -28% |
| Q1 2026 | $2.7K | +185% |
| Q4 2025 | $3.6K | -21% |
| Q3 2025 | $2.9K | -57% |
| Q2 2025 | $7.5K | -5% |
| Q1 2025 | $940 | -94% |
| Q4 2024 | $4.5K | -15% |
CDIO's revenue is recovering but still below its 2024 peak: $3,590 last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -48194% | +11757 points |
| Q2 2026 | -27951% | -5493 points |
| Q1 2026 | -66598% | +106865 points |
| Q4 2025 | -41160% | -7551 points |
| Q3 2025 | -59951% | -38538 points |
| Q2 2025 | -22458% | -6162 points |
| Q1 2025 | -173464% | -147359 points |
| Q4 2024 | -33608% | -4569 points |
CDIO's operating margin was −48194% last quarter, up 11757 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CDIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CDIO on profitability, with a higher operating margin.
CDIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.5M | +$40.4K |
| Q2 2026 | -$1.3M | +$247.8K |
| Q1 2026 | -$1.6M | -$158.1K |
| Q4 2025 | -$1.4M | +$34.1K |
| Q3 2025 | -$1.6M | -$375.6K |
| Q2 2025 | -$1.6M | -$211.9K |
| Q1 2025 | -$1.4M | -$152.9K |
| Q4 2024 | -$1.4M | +$826.8K |
CDIO has burned cash in almost every quarter: −$6M over the past year, against −$6M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CDIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CDIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +70% | +1.2M shares |
| 3 years | +833% | +2.6M shares |
CDIO has 3M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CDIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CDIO Net Leverage
CDIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CDIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.5 | Neutral |
| Stochastic | 26.3 | Neutral |
CDIO's weekly RSI is 48 (neutral) and its Stochastic is 26 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CDIO PE vs Healthcare Sector
CDIO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CDIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.79 | 4.5% above |
| 20 week MA | $1.83 | 2.2% above |
| 50 week MA | $2.18 | 14% below |
| 100 week MA | $5.53 | 66% below |
| 200 week MA | $21.2 | 91% below |
CDIO has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 91% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CDIO on trend strength, trading above more of its moving averages.
CDIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $294.6 | $32.4 | -89% |
| 2023 | $32.4 | $74.7 | +131% |
| 2024 | $74.7 | $27.8 | -63% |
| 2025 | $27.8 | $3.33 | -88% |
| 2026 YTD | $3.33 | $1.87 | -44% |
CDIO's yearly returns have swung widely, from +131% in 2023 to −89% in 2022. It's down 44% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CDIO on returns for 2026, with the stronger performance.